All Stories

  1. Exploring the temporal relationship between stigma, disease manifestations, and health outcomes in post COVID-19 condition: a longitudinal descriptive study
  2. The effect of pollutant exposure on cough in progressive pulmonary fibrosis
  3. Which trial do we need? Combination regimen for individuals exposed to multidrug-resistant Mycobacterium tuberculosis
  4. Impact of Clinical Practice Guidelines on Palliative Care and Health Outcomes in Idiopathic Pulmonary Fibrosis in a Canadian Province
  5. Decoding objective cough features in progressive pulmonary fibrosis: A 6-month feasibility study
  6. Patient and provider perceptions of the impact of COVID-19 on tuberculosis healthcare access and delivery: A qualitative study of the complexities of a pandemic within a pandemic
  7. The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation
  8. Refining the definition of miliary/disseminated tuberculosis in Canada
  9. Percent Predicted vs. Absolute Six-Minute Walk Distance as Predictors of Lung Transplant-Free Survival in Fibrosing Interstitial Lung Diseases
  10. “A Mighty Flame Can Follow a Tiny Spark”: Is This the Case of c-Jun N-Terminal Kinase 1 Inhibitors in Idiopathic Pulmonary Fibrosis?
  11. Understanding facilitators and barriers to oxygen therapy for patients with interstitial lung disease
  12. Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?
  13. Factors associated with phenotypes of dyspnea in post-COVID-19 condition: a cross-sectional study
  14. The clinical impact of heart failure with preserved ejection fraction in interstitial lung diseases
  15. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study
  16. The diagnostic pathway for patients with interstitial lung disease: a mixed-methods study of patients and physicians
  17. Use of 6‐minute walk distance to predict lung transplant‐free survival in fibrosing non‐IPF interstitial lung diseases
  18. Early Organ Metastasis in Granulomatous Mycosis Fungoides: A Systematic Review
  19. Macrolides and Asthma Therapy
  20. Chapitre 15: Le suivi du rendement du programme de lutte antituberculeuse
  21. Characterizing long-COVID brain fog: a retrospective cohort study
  22. Less Social Deprivation Is Associated With Better Health-Related Quality of Life in Asthma and Is Mediated by Less Anxiety and Better Sleep Quality
  23. A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings
  24. Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association
  25. Skin disorders and interstitial lung disease: Part I—Screening, diagnosis, and therapeutic principles
  26. Fibrotic or nonfibrotic interstitial lung disease in patients with primary Sjögren syndrome
  27. No one left behind: review of precision medicine and cystic fibrosis—how the changing approach to cystic fibrosis treatment might lead to tailored therapies for all
  28. Reliability and validity of the post COVID-19 condition stigma questionnaire: a prospective cohort study
  29. A case series of dermatomyositis following SARS-CoV-2 vaccination
  30. Reflecting on the relationship between residential schools and TB in Canada
  31. Responding to the post-pandemic crisis: post-exposure prophylaxis for TB
  32. Reference equations for oscillometry and their differences among populations: a systematic scoping review
  33. Persistent dyspnea after COVID-19 is not related to cardiopulmonary impairment; a cross-sectional study of persistently dyspneic COVID-19, non-dyspneic COVID-19 and controls
  34. Chapter 15: Monitoring tuberculosis program performance
  35. Immunomodulatory treatment of interstitial lung disease
  36. COVID‐19 hospitalization is associated with pulmonary/diffusion abnormalities but not post‐acute sequelae of COVID‐19 severity
  37. Macrolides versus placebo for chronic asthma
  38. Exertional intolerance and dyspnea with preserved lung function: an emerging long COVID phenotype?
  39. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management
  40. Disseminated TB: still being missed and misunderstood
  41. Six-minute walking test outweighs other predictors of mortality in idiopathic pulmonary fibrosis. A real-life study from the Swedish IPF registry
  42. Early referral to palliative care in IPF – pitfalls and opportunities in clinical trials
  43. RA-ILD: does more detailed radiological classification add something to our knowledge of this condition?
  44. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden
  45. What patients with Idiopathic Pulmonary Fibrosis and caregivers want – Filling the currents gaps with patient reported outcomes and experience measures
  46. Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015
  47. Pulmonary outcomes in adults with a history of Bronchopulmonary Dysplasia differ from patients with asthma
  48. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study
  49. An Atypical Case of Idiopathic Pulmonary Fibrosis in a Patient from Africa
  50. Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden
  51. Latent tuberculous infection among foreign-born individuals applying to shelters in the metropolitan area of Milan
  52. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
  53. Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions
  54. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study
  55. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
  56. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?
  57. Lung function development after preterm birth in relation to severity of Bronchopulmonary dysplasia
  58. Humoral immune profiling of mycobacterial antigen recognition in sarcoidosis and Löfgren’s syndrome using high-content peptide microarrays
  59. Immune recognition surface construction of Mycobacterium tuberculosis epitope-specific antibody responses in tuberculosis patients identified by peptide microarrays
  60. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
  61. Need for combined interventions and operational research to tackle tuberculous meningitis
  62. Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry
  63. T-Cell Therapy: Options for Infectious Diseases: Table 1.
  64. Macrolides for chronic asthma
  65. Recurrent respiratory infections and unusual radiology: a woman with Kartagener's syndrome
  66. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis
  67. Extra-pulmonary tuberculosis and Xpert® MTB/RIF: all about meta-analyses?
  68. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review
  69. No association between Birt-Hogg-Dubé syndrome skin fibrofolliculomas and the first 10 described human polyomaviruses or human papillomaviruses
  70. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial
  71. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
  72. Chronic empyema: importance of preventing complications in the management of pleural effusions
  73. Isoniazid preventive treatment: predictors of adverse events and treatment completion
  74. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence: Table 1–
  75. Intra-abdominal bleeding during treprostinil infusion in a patient with pulmonary arterial hypertension
  76. Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections
  77. Risk factors associated with pulmonary tuberculosis
  78. Trends and challenges in tuberculosis in a medium-sized southern European setting [Notes from the field]
  79. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
  80. "Interferon-  release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis." R. Diel, D. Goletti, G. Ferrara, G. Bothamley, D. Cirillo, B. Kampmann, C. Lange, M. Losi, R. Markova, G.B. Migliori,...
  81. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  82. Tuberculosis in prisons: anatomy of global neglect
  83. Screening of immigrants in the UK for latent tuberculosis
  84. Xpert MTB/RIF test for tuberculosis
  85. A Decade of Interferon-γ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection withMycobacterium tuberculosis?
  86. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis
  87. The best on infections: update from the 2010 ERS Congress
  88. Tuberculosis in prisons in sub-Saharan Africa – the need for improved health services, surveillance and control
  89. Interferon-  release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis
  90. TB or not TB: update from the ERS Respiratory Infection Assembly 10
  91. Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection
  92. Performance of Tests for Latent Tuberculosis in Different Groups of Immunocompromised Patients
  93. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET
  94. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis
  95. Mycobacterium tuberculosis Induces CCL18 Expression in Human Macrophages
  96. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?
  97. Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TBassay
  98. Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results
  99. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
  100. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  101. Clinical and operational value of the extensively drug-resistant tuberculosis definition
  102. Combination fluticasone and salmeterol vesus fixed dose combination budesonide and formoterol for chronic asthma in adults and children
  103. Extensively Drug-resistant Tuberculosis, Italy and Germany
  104. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs
  105. Blood tests for diagnosis of tuberculosis – Authors' reply
  106. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study
  107. Macrolides for chronic asthma
  108. Routine Hospital Use of a New Commercial Whole Blood Interferon-γ Assay for the Diagnosis of Tuberculosis Infection
  109. Macrolides for chronic asthma
  110. Community Acquired Pneumonia in Internal Medicine: A One-Year Retrospective Study Based on Pneumonia Severity Index
  111. Macrolides in the treatment of asthma and cystic fibrosis
  112. Corticosteroids for idiopathic pulmonary fibrosis
  113. Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000
  114. Macrolides for chronic asthma